News for Natera, Inc. (NTRA)

Shares of Natera Inc (NTRA) surged 4.28% in mid-day trading on Jun 4. The stock reached an intraday high of $167.76, before settling at $167.00, up from its

Key Takeaways: Natera's molecular residual disease test, Signatera, has received expanded Medicare coverage, significantly widening its availability across

Summary Natera Inc (NTRA), a leader in cell-free DNA and precision medicine, announced that its genome-based Signatera MRD assay has received Medicare coverage

Natera's (NTRA) Signatera Genome assay achieves remarkable 94% sensitivity and 100% specificity in pan-cancer detection. Signatera can predict long-term

Shares of Natera Inc (NTRA) surged 3.07% in mid-day trading on May 27. The stock reached an intraday high of $158.38, before settling at $158.02, up from it

Billionaire Stanley Druckenmiller has now allocated more than a billion dollars to three under-the-radar equities.

Summary Natera Inc (NTRA), a leader in cell-free DNA and precision medicine, announced that it will present data from over 25 studies involving its Signatera te

Natera delivered stellar Q1 results, with revenue and EPS beating expectations. Click here to see why NTRA stock is a Buy.

Insights from Stanley Druckenmiller (Trades, Portfolio)'s First Quarter 2025 13F Filing Stanley Druckenmiller (Trades, Portfolio) recently submitted the 13F fi

Exploring the Latest 13F Filing and Investment Strategies Lee Ainslie (Trades, Portfolio) recently submitted the 13F filing for the first quarter of 2025, prov

On May 15, 2025, Piper Sandler analyst David Westenberg updated his rating for Natera (NTRA), maintaining an "Overweight" position. The rating remains consisten

Below is the April 2025 Monthly Update for the Liberty All-Star Growth Fund, Inc. (NYSE: ASG). Liberty All-Star Growth Fund, Inc. Ticker: ASG Monthly Update,

Piper Sandler has increased its price target for Natera (NTRA) from $205 to $210 in light of the latest quarterly performance. The firm maintains an Overweight

We came across a bullish thesis on Natera, Inc. (NTRA) on Substack by FJ Research. In this article, we will summarize the bulls’ thesis on NTRA. Natera, Inc. (NTRA)’s share was trading at $162.57 as of May 8th. Natera is emerging as one of the most pivotal companies in the transformation of global healthcare, and its significance […]

UBS analyst Elizabeth Garcia has updated her assessment of Natera (NTRA) by maintaining the firm's

BTIG has lifted its price target for Natera (NTRA) from $190 to $195, maintaining a Buy rating on the stock. The adjustment follows Natera's impressive first-qu

Barclays has adjusted its price target for Natera (NTRA) from $160 to $190. This decision comes following the company's recent earnings report, prompting the fi

Natera, Inc. (NASDAQ:NTRA) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ETCompany ParticipantsMichael Brophy - CFOSteve Chapman - CEOSolomon...

ARK ETFs sold 376,874 Palantir (PLTR) shares for $46.65 million, continuing a week-long reduction, while investing $10.45 million in 237,374 Guardant Health (GH) shares, signaling a shift from data analytics to precision oncology. Significant purchases included $10.17 million for 283,186 Twist Bioscience (TWST) shares and $8.75 million for 55,623 Natera…